**Participant flow**

**Baseline characteristics**

|  |  |
| --- | --- |
| **Characteristic** | **Patients included** |
| Age: years |  |
|  *Mean (S.D.)* | 61.7 (15.4) |
|  *Range* | 20.1 – 90.2 |
| Gender: no (%) |  |
|  *Men* | 70 (57%) |
|  *Women* | 53 (43%) |
| Starting dose: no (%) |  |
|  *10 mg/day* | 12 (9.8) |
|  *5 mg/day* | 106 (86.2) |
|  *5 mg/2 days* | 3 (2.4) |
|  *2.5 mg/2 days* | 1 (0.8) |
|  *unknown* | 1 (0.8) |
| Condition: no (%) |  |
|  *Idiopathic OAB* | 83 (67.5) |
|  *Neurogenic OAB* | 40 (32.5) |
| S.D.: Standard deviation |  |

**Outcome measures**

|  |
| --- |
| **Persistence rate solifenacin after one year** |
|  | Patients still using | Patients discontinued | Lost to FU |
| ***All patients*** | ***50 (40.7%)*** | ***61 (49.6%)*** | ***12 (9.7%)*** |
| **Neurogenic OAB** | 23 (57.5%) | 13 (32.5%) | 4 (10%) |
| **Idiopathic OAB** | 27 (32.5%) | 48 (57.8%) | 8 (9.7%) |

**Adverse events**

There were no adverse events associated with this trial.